Home

Moderate to Severe Plaque Psoriasis

Cimzia demonstrates durable efficacy through pooled data from the Cimzia arms of the CIMPASI 1 and CIMPASI 2 trials.2

Scroll or click the links to jump to any section below:
Jump Menu
Key studies
Efficacy
Safety profile
Dosing
Unique molecular structure
Women of childbearing age
References
Dosing
Unique molecular structure
Off
Did you know?

Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1

Click here for full details

Off

Efficacy

See the efficacy data offered by Cimzia in PsO

Key study
Key efficacy data

Cimzia demonstrates durable efficacy for the treatment of moderate-to-severe plaque psoriasis.

View this data
Off

Safety profile

Cimzia in PsO: Key Safety Profile Data

Key study
Safety profile data

Cimzia was studied in 1112 patients with psoriasis in controlled and open-label studies for up to 3 years.1

View data
Off

Dosing

Dosing and administration across all indications1

Key study
Dosing guide

Cimzia maintenance dosing regimen is preceded by a loading dose across all indications1

See dosing guide
eye icon eye icon See Also
A step-by-step guide to injecting with the Cimzia AutoClicks pre-filled pen
Step-by-step guide to injecting with the Cimzia pre-filled syringe
Off

Unique molecular structure

Cimzia is a PEGylated, FC free anti-TNF1

Key study
FC free anti-TNF

Cimzia is the first PEGylated, FC free anti-TNF indicated for the treatment of severe active Axial Spondyloarthritis, active Psoriatic Arthritis, moderate to severe Plaque Psoriasis, and moderate to severe Rheumatoid Arthritis inadequately controlled with prior therapy.1,6,10-12

Cimzia's licensed indications include severe active Axial Spondyloarthritis (axSpa), active Psoriatic Arthritis (PsA), moderate to severe Plaque Psoriasis (PSO), and moderate to severe Rheumatoid Arthritis (RA) inadequately controlled with prior therapy.1

See more
Off

Women of childbearing age

Reducing the treatment burden for women of childbearing age

Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.13 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.14

Sandra's Story
(Cimzia should only be used during pregnancy if clinically needed.1 )

Key study
Sandra's Story

A hypothetical journey for a patient

View here
eye icon eye icon See Also
CRIB
CRADLE
Off

References

  1. Cimzia® Summary of Product Characteristics. [Accessed April 2021].
  2. Gordon, K et al. 2020. British Journal of Dermatology, DOI 10.1111/bjd.19393.
  3. Enbrel® Summary of Product Characteristics. [Accessed April 2021].
  4. Remicade® Summary of Product Characteristics. [Accessed April 2021].
  5. Humira® Summary of Product Characteristics. [Accessed April 2021].
  6. Cosentyx® Summary of Product Characteristics. [Accessed April 2021].
  7. Taltz® Summary of Product Characteristics. [Accessed April 2021].
  8. Simponi® Summary of Product Characteristics. [Accessed April 2021].
  9. Weir N, et al. Therapy. 2006;3(4):535–545.
  10. Furst D. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S5–12.
  11. Porter C, et al. J Reprod Immunol. 2016;116:7–12.
  12. Roopenian D, et al. Nat Rev Immunol. 2007;7(9):715–725.
  13. NHS England 2017 Commissioning framework for biological medicines (including biosimilar medicines) https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf [Accessed April 2021]
  14. NHS RightCare Musculoskeletal (MSK) Workstream
    https://www.england.nhs.uk/rightcare/workstreams/musculoskeletal-msk/ [Accessed April 2021]
Off
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Click here for Prescribing Information

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: June 2021
IE-P-CZ-AS-2100053